Role of computed tomography findings, complete blood count parameters and systemic inflammatory markers for predicting the severity in interstitial lung diseases Markers Predicting Prognosis in ILD
Main Article Content
Keywords
CT, Fibrosis, Neutrophil-lymphocyte ratio, Platelet-neutrophile ratio, Warrick score
Abstract
Background and Objectives: The present study aimed to find quantitative and semiquantitative methods to detect the development of fibroproliferative processes at an early stage and predict the severity and prognosis of the disease in interstitial lung diseases (ILDs) using High-Resolution Computed Tomography (HRCT), Pulmonary Function Tests (PFTs) and Complete Blood Count (CBC) parameters.
Materials and methods: A total of 63 patients (26 female and 37 male) who were admitted to our hospital between January 2014 and January 2018, whose follow-ups were regular and who underwent HRCT, PFT, and CBC examinations on the same day, were included in our study. The median age of the patients included was 65 years (range: 47-79).
Results: There were significant differences among the mild, moderate, and severe form ILD groups created using the Warrick scoring system for NLR, neutrophil count, and PNR values (p = 0.025, 0.035, 0.006, respectively). Also, there were significant differences among the groups for FVC, FEV1/FVC, PAD, RAA, RV/LV ratio, MLnMD, and MLnC values. Correlation analyses between the parameters revealed significant relationships between Warrick Score, and NLR and neutrophil count, PNR, FVC, FEV1/FVC, PAD, RAA, RV/LV ratio, MLnMD, and MLnC .
Conclusions: The results of the present study suggested that NLR, neutrophil count, and PNR values could be used as objective evaluation criteria to determine the severity and prognosis in interstitial lung diseases. Also, usage of Warrick Score, FVC, FEV1/FVC, PAD, RAA, RV/LV ratio, MLnMD, and MLnC values could provide quantitative and semiquantitative data for an objective evaluation. Carrying out multicenter studies and creating a scoring system using these parameters could create standardization in determining the prognosis of patients with ILD.
References
2- Kumar V, Abbas AK, Fausto N, Mitchell RN. Robbins Temel Patoloji 8. Baskı. Çevirmen: Çevikbaş U, Güllüoğlu M, Mete Ö. Nobel Tıp Kitabevi, 2008; 128-155.
3- Xaubet A, Agustí C, Luburich P, et al. Pulmonary function tests and CT scan in the management of idiopathic pulmonary fibrosis. American journal of respiratory and critical care medicine 1998; 158: 431-6.
4- Müller N. Clinical value of high-resolution CT in chronic diffuse lung disease. AJR American journal of roentgenology 1991; 157: 1163-70.
5- Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. American journal of respiratory and critical care medicine 2013; 188: 733-48.
6- Reynolds HY. Diagnostic and management strategies for diffuse interstitial lung disease. Chest 1998; 113: 192-202.
7- King TE, Flaherty KR, Hollingsworth H. Approach to the adult with interstitial lung disease: clinical evaluation. 2018.
8- Lee SH, Park MS, Kim SY, et al. Factors affecting treatment outcome in patients with idiopathic nonspecific interstitial pneumonia: a nationwide cohort study. Respir Res 2017; 18: 204.
9- American Thoracic Society/European Respiratory Society International Multidiciplinary Consensus Classification of Idiopathic İnterstitial Pneumonias. Am J Respir Crit Care Med 2002; 165:277-304.
10- Schwartz MI, King TE. Aprroach to the evaluation of interstitial lung disease. Scwartz MI, King TE, editors. Interstitial lung disease Textbook of interstitial lung diseases. 4 th ed. London, 2003; 1-30.
11- Britton J, Evans A. Diffuse lung disease: Approach to diagnosis. In: Albert R, Spiro S, Jett J editors. Comprehensive Respiratory Medicine London 1999; 78-221.
12- Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment. Intenational Consensus Statement. Am J Respir Crit Care Med 2000; 161:646-664.
13- Bellia M, Cannizzaro F, Scichilone N, et al. HRCT and scleroderma: semiquantitative evaluation of lung damage and functional abnormalities. La Radiologia Medica 2009; 114(2):190–203.
14- İbrahim İMH, Gamal SM, Salama AM, Khairy MA. Systemic sclerosis: correlation between lung abnormalities on high-resolution computed tomography (HRCT) and pulmonary function tests (PFTs), Egyptian Journal of Radiology and Nuclear Medicine 2020; 51:98.
15- Warrick JH, Bhalla M, Schabel SI, et al. High resolution computed tomography in early scleroderma lung disease. The Journal of rheumatology 1991; 18(10):1520–1528.
16- Assayag D, Kaduri S, Hudson M, Hirsch A, Baron M. High Resolution Computed Tomography Scoring Systems for Evaluating Interstitial Lung Disease in Systemic Sclerosis Patients. Rheumatology 2012; S1:003.
17- Afeltra A, Zennaro D, Garzia P, et al. Prevalence of interstitial lung involvement in patients with connective tissue diseases assessed with high-resolution computed tomography. Scand J Rheumatol 2006; 35:388–394.
18- Yılmazer B, Gümüştaş S, Coşan F, et al. High resolution computed tomography and rheumatoid arthritis: semi quantitative evaluation of lung damage and its correlation with clinical and functional abnormalities. La Radiologia Medica 2015; DOI 10.1007/s11547-015-0590-5.
19- Souza CA, Müller NL, Lee KS, Johkoh T, Mitsuhiro H, Chong S. Idiopathic Interstitial Pneumonias: Prevalance of Mediastinal Lymph Node Enlargement in 206 Patients. American Journal of Roentgenology 2006; 186 (4): 995-9.
20- Farrokh D, Abbasi B, Fallah-Rastegar Y, Mirfeizi Z. The Extrapulmonary Manifestations of Systemic Sclerosis on Chest High Resolution Computed Tomography. Journal of Respiratory Disease, Thoracic Surgery, İntensive Care and Tuberculosis 2015; 14(3): 193-200.
21- Zompatori M, Leona MB, Giannotta M, et al. Pulmonary hypertension and systemic sclerosis: the role of high-resolution computed tomography. La Radiologia Medica 2013; DOI 10.1007/s11547-013-0934-1.
22- Atilla N, Çetin GY, Balkarlı A. Association of neutrophil/lymphocyte ratio with the degree of interstitial lung disease in systemic sclerosis. Turk J. Med 2016; 46:1871-1874.
23- Yang W, Wang X, Zhang W, et al. Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio are 2 new inflammatory markers associated with pulmonary involvement and disease activity in patients with dermatomyositis. Clinica Chimica Acta 465 2017; 11–16.
24- Tezcan D, Turan C, Yılmaz S et al. What do simple hematological parameters tell us in patients with systemic sclerosis?. Acta Dermatovenerologica 2020;29:101-107.
25- Chen Q, Chen D, Xu X et al. Platelet/Lymphocyte, Lymphocyte/Monocyte and Neutrophil/Lymphocyte Ratios as Biomarkers in Patients with Rheumatoid Arthritis and Rheumatoid
Arthritis-Associated Interstitial Lung Disease. Med Sci Monit. 2019; 25: 6474-6481.
26- Cakmak G, Can TS, Gundogdu S et al.
Relationship between abnormalities on high-resolution computerized tomography, pulmonary function, and bronchoalveolar lavage in progressive systemic sclerosis. Sarcoidosis Vasc Diffuse Lung Dis 2016; 33: 349-354.
27- Nadrous HF, Pellikka PA, Krowka MJ, et al. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest 2005;128:2393-99.
Article Sidebar
Article Details
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
